Hormonal Contraceptives Market Definition

The hormonal contraceptives market consists of sale of hormonal contraceptives and related services by entities (organizations, sole traders, and partnerships) that produce hormonal contraceptives that are used as a birth control method acting on the endocrine system of the human body to prevent pregnancy. Hormonal contraceptives refers to birth control methods that act on the endocrine system and regulates the hormonal cycle using estrogens and progestogens to prevent pregnancy in women (there are currently no approved hormonal contraceptives for use in men). Hormonal contraceptives are available in different forms such as pills, injections, implants, and intrauterine devices and contain a small amount of human-made estrogen and progestogen hormones. These hormones inhibit the natural menstrual cycle and prevent pregnancy.

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are. The main drug classes of branded generics are alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and other drugs. The alkylating agents of branded generics refer to a subclass of antineoplastic or anticancer medications that work by preventing the conversion of DNA into RNA, which halts the creation of proteins. Alkylating chemicals change the hydrogen atoms on DNA to alkyl groups, which causes cross-links to form inside the DNA chain and has cytotoxic, mutagenic, and cancerous consequences. The various routes of administration of branded generics include topical, oral, parenteral, and other routes. They are in various medical conditions including oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and other diseases. The branded generics market research report is one of a series of new reports from The Business Research Company that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global branded generics market size grew from $304.16 billion in 2022 to $329.98 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The branded generics market size is expected to grow to $464.58 billion in 2027 at a CAGR of 8.9%. The increasing prevalence of chronic diseases will drive the growth rate of branded generics market. Chronic diseases are long-lasting sicknesses that often cannot be healed, however, they are curable and controllable. Chronic diseases are increasing due to the increasing use of tobacco products, poor nutrition, physical inactivity, excessive use of alcohol, and others. Customers across the globe are more inclined toward branded generics to treat chronic diseases as they purchase them at a lower cost than usual medications. For instance, in September 2020, according to a research report published by American Action Forum, chronic disease prevalence and costs are rising in the United States. They are expected to keep rising as the disease prevalence among children and young adults rises. Chronic disease is a serious healthcare problem since the rising cost of chronic disease in the United States totals $3.7 trillion annually, which is around 19.6% of the country's gross domestic product. Thus an increase in the prevalence of chronic diseases is expected to boost the demand for branded generics during the forecast period. The strategic partnership is a key trend in the branded generics market. The companies operating in branded generics are entering into a partnership with relevant companies to leverage each other's resources and expand into new markets. In December 2021, Biocon Ltd., an India-based fully integrated biopharmaceutical company that develops affordable biosimilars, generic formulations & complex APIs, entered into a partnership with Tabuk Pharmaceuticals. The partnership will open the door for Biocon's entry into the MENA area, which will now include Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. This will help create a robust worldwide portfolio of goods, either directly or through strategic alliances, to provide patients all over the world with access to inexpensive treatments. These medications' marketing authority will be held by Tabuk Pharmaceuticals, which is also in charge of their registration, importation, and promotion in Saudi Arabia and other Middle Eastern nations. Tabuk Pharmaceuticals is a Saudi Arabia-based company that manufactures and markets branded and generic pharmaceutical products. In July 2021, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales. It will result in the growth of value offer and market share of Lupin in the Australian market. Southern Cross Pharma Pvt Ltd (SCP) is an Australia-based pharmaceutical company engaged in developing, registering, and distributing generic products. Major players in the branded generics market are Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, AstraZeneca, Apotex Inc., Zydus Cadila, Dr. Reddy's Laboratories Ltd., Viatris, Inc., and Valeant Pharmaceuticals International, Inc., North America was the largest region in the branded generics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global branded generics market is segmented - 1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering Drugs, Anti-depressants, Anti-psychotics, Anti-Epileptics, Other Drugs 2) By Route of Administration: Topical, Oral, Parenteral, Other Routes of Administration 3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-inflammatory, Other Applications

Anti-thyroid drugs refer to agents that function by preventing the manufacture of thyroid hormones or by reducing the action of thyroid hormones. Additionally, they are suggested for use in radioactive iodine uptake tests to assess thyroid function and safeguard the thyroid gland in case of radiation exposure. The main types of anti-thyroid drugs are thionamides (inhibition of hormone synthesis) and iodides (inhibition of hormone release). Ethionamide drugs pharmacologically normalize thyroid hormone levels. The drugs are administered orally, and intravenously, and others are distributed by wholesalers/distributors, retail chains, online distribution, and others. The anti-thyroid drugs market research report is one of a series of new reports from The Business Research Company that provides anti-thyroid drugs market statistics, including anti-thyroid drugs industry global market size, regional shares, competitors with an anti-thyroid drugs market share, detailed anti-thyroid drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-thyroid drugs industry. This anti-thyroid drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anti-thyroid drugs market size will grow from $2.45 billion in 2022 to $2.52 billion in 2023 at a compound annual growth rate (CAGR) of 3.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anti-thyroid drugs market size is expected to grow to $2.78 billion in 2027 at a CAGR of 2.5%. Graves’ disease is one of the direct causes of hyperthyroidism and the incidence of Graves’ disease increasing. According to a research study published in 2020, in developed countries, Graves' disease (GD) is the most common cause of hyperthyroidism. It is more common between the ages of 30 and 60, and women are 5–10 times more likely than men. Genetic predisposition accounts for 79% of the risk for GD, while environmental factors account for 21%. Owing to the rising number of Grave’s disease, people suffering from hyperthyroidism are also increasing. This results in the overall growth in the demand for anti-thyroid drugs thereby driving the market. The anti-thyroid drugs market is being restrained by the side effects of medication used to treat hyperthyroidism conditions. There are many side effects associated with the medication used to treat hyperthyroidism. For instance, according to a study it was found that the two most commonly used anti-thyroid medications propylthiouracil (PTU) and methimazole (MMI) cause hepatotoxicity and death in children and major abnormalities in the fetus. Associations for thyroid care are launching initiatives to spread more awareness about thyroid disorders, updates on the recent treatment methods, and other summaries regarding various research on thyroid disorders. In the USA, nearly 60% of the population suffering from hyperthyroidism are unaware and remain undiagnosed. To curb these issues, associations including the American Thyroid Association (ATA) are making an impact by educating people about thyroid disorders. Similarly, the Thyroid Foundation of Canada has also initiated awareness to awaken public interest and awareness about thyroid diseases including hyperthyroidism. Other associations that are launching initiatives and awareness programs include the American Academy of Otolaryngology and the British Thyroid Foundation among others. Major players in the anti-thyroid drugs market are Mylan N.V., Abbott Laboratories, GlaxoSmithKline PLC., Merck & Co., AbbVie Inc., Pfizer Inc., Allergan PLC, RLC LABS, Amgen Inc., and Lannett Company Inc. North America was the largest region in the anti-thyroid drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global anti-thyroid drugs market during the forecast period. The regions covered in the global anti-thyroid drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-thyroid drugs market consists of sales of levothyroxine, propylthiouracil, and methimazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anti-thyroid drugs market is segmented - 1) By Drug Type: Thionamides (Inhibition of hormone synthesis), Iodides (Inhibition of hormone release) 2) By Route of Administration: Oral, Intravenous, Other Route of Adminitration 3) By Distribution Channel: Wholesaler/Distributors, Retail Chain, Online Distribution, Other Distribution Channels

Breast cancer monoclonal antibodies (mAbs) refer to the use of antibodies in the treatment of both early-stage and advanced breast cancer. It functions by identifying and locating particular proteins on cancer cells. Every MAB recognises a different protein. Therefore, different MABs must be created to target various cancer types. They kill the cancer cell in various ways depending on the protein they are targeting. The main types of breast cancer monoclonal antibodies are naked mAbs and conjugated mAbs. Naked mAbs are antibodies that are free of any drugs or radioactive materials. They are self-contained. The most prevalent type of mAb used to fight cancer is this one. The different types of treatments include chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, and hormone therapy, and they are used in various sectors such as hospitals, and retail pharmacies. The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports from The Business Research Company that provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global breast cancer monoclonal antibodies market grew from $16.67 billion in 2022 to $17.81 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The breast cancer monoclonal antibodies market is expected to grow from $23.36 billion in 2027 at a CAGR of 7.0%. Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibody market’s growth. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. According to Breastcancer.org, a US-based non-profit organization, as of January 2020, there were more than 3.8 million women in the US with a history of breast cancer. This includes women who are currently being treated and women who have completed the treatment. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibody market. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homoeopathic product market is projected to reach $18.6 billion by the end of 2027. The National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customise personalised vaccines. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market. Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received a placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market. In November 2020, Merck & Co., Inc., a US-based research-oriented biopharmaceutical company, acquired VelosBio, Inc., for an amount of $2.75 billion. Through this acquisition, Merck will strengthen its oncology drug pipeline with VLS-101 for the treatment of patients with hematologic malignancies and solid tumours and its research capabilities in the field of cancer research. VelosBio, Inc. is a US-based clinical-stage biopharmaceutical company specialising in the development of brand-new antibody-drug conjugates ("ADCs") to treat solid tumours and hemological malignancies. Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma. North America was the largest region in the breast cancer monoclonal antibodies market in 2022. The regions covered in the global breast cancer monoclonal antibodies (mAbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer monoclonal antibodies (mAbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The breast cancer monoclonal antibodies (mAbs) market consists of sales of trastuzumab, pertuzumab, bevacizumab, and rituximab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer monoclonal antibodies market is segmented - 1) By Product: Naked Mabs, Conjugated Mabs 2) By End-User: Hospitals, Retail Pharmacies 3) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy

G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumours, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it. The main types of G-CSF are lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco), and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablets, capsules, and others and are used in oncological diseases, blood disorders, growth hormone deficiencies, and chronic and autoimmune disorders, among others. The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global g-csf (granulocyte colony stimulating factors) market grew from $7.99 billion in 2022 to $8.43 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The g-csf (granulocyte colony stimulating factors) market is expected to grow from $9.94 billion in 2027 at a CAGR of 4.2%. The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in December 2020, according to the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency that publishes research and data on cancer, it is anticipated that 28.4 million new cases of cancer will be diagnosed worldwide in 2040, up 47% over the anticipated 19.3 million cases in 2020, primarily due to population growth and aging. G-CSF is a class of growth factors that produce white blood cells in the bone marrow to minimise the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF market. The high cost is a key factor limiting the growth of the G-CSF market. Improved chemotherapy administration is responsible for the rise in immediate medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the cost of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (granulocyte colony stimulating factor) market. Companies in the G-CSF market are focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For example, in 2022, Evive Biotech, a Singapore based biopharmaceutical company collaborated with Germany based pharmaceutical company, APOGEPHA to enter into an exclusive long-term license agreement for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a novel dimeric G-CSF long-acting fusion protein without pegylation. In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, G-CSF drugs would be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of biosimilars for the treatment of eye related diseases. Major players in the G-CSF (granulocyte colony stimulating factors) market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, StadaArzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories, and Celltrion Inc. North America was the largest region in the G-CSF granulocyte colony stimulating factors market in 2022. The regions covered in the global G-CSF (granulocyte colony stimulating factor) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the G-CSF (granulocyte colony stimulating factor) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global G-CSF (granulocyte colony stimulating factors) market is segmented - 1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex) 2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications 3) By Product: Tablet, Capsule, Other Products

Hormonal contraceptive refers to a method of birth control that stops pregnancy using hormones. There are numerous types. Some can be undone, while others are irreversible. Some varieties can also aid in the prevention of STDs. The main types of products in oral contraceptive pills are injectable birth control, emergency contraceptive pills, vaginal rings, and others. Any class of synthetic steroid hormones which inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body is known as oral contraceptive pills or birth control pills. The different hormones include progestin-only, and combined hormones and are used by hospitals, homecare settings, gynecologycenters, clinics, and ambulatory surgical centers. It is distributed through various channels such as drug stores, gynecology or fertility clinics, e-commerce, and others. The hormonal contraceptives market research report is one of a series of new reports from The Business Research Company that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hormonal contraceptives market size will grow from $13.47 billion in 2022 to $13.78 billion in 2023 at a compound annual growth rate (CAGR) of 2.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hormonal contraceptives market size is expected to grow to $14.56 billion in 2027 at a CAGR of 1.4%. Increased awareness about the benefits and use of contraceptives is a major factor driving the hormonal contraceptives market. According to the World Health Organization (WHO), 16 million girls worldwide aged 15-19 give birth every year which accounts for approximately 11% of all births globally. To prevent these unplanned births global awareness programs such as It’s your life, it’s your future by the WHO and world contraception day was initiated. The London Summit on Family Planning urged governments, international agencies, and another private sectors to commit to improving access to voluntary family planning. This gave rise to the global partnership, Family Planning 2020 (FP2020). FP2020 has created momentum worldwide on issues such as access to contraceptives, more innovation, and greater accountability in family planning efforts. For example, India will have spent USD$3 billion by 2020 to spread awareness and improve family planning in the country. Moreover, in 2020, according to the United Nations Department of Economic and Social Affairs, about 1.1 billion women aged between 15 and 49 are considered to need family planning. The market for hormonal contraceptive drugs is restrained by the growing use of biologics in place of traditional chemical drugs. Biologics are medicines containing one or more substances derived from a biological source like micro-organisms, animal cells, or human cells. The ability to interact with specific targets puts these medicines above any other drugs, thus hampering the market of chemical-hormonal contraceptive drugs. Companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. The pill is already being sold as an over-the-counter product. Some of the top companies that produce and sell chewable low-dose oral contraceptives, for instance, are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. Manufacturers in the hormonal contraceptives market should abide by many strict regulations about labeling hormonal contraceptives, and are all supervised by regulatory authorities. For instance, the US FDA has drafted a new set of guidance and labeling recommendations in the hormonal contraceptives market. The main purpose of PLR is to enhance the safety and usage of the particular prescribed drug by providing healthcare providers with clear prescription information (PI). The FDA mandates all hormonal contraceptives to mention the effectiveness of the drug in preventing STDs and any other relevant information regarding the effectiveness of the drug. The FDA considers that communicating information regarding pregnancy rates to the users of these contraceptive drugs is essential for safety and effective usage. Major players in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc., Pfizer, Allergan, Afaxys Inc., TevaPharma Industries Ltd., Agile Therapeutics, HLL Lifecare Limited, Lupin Pharmaceuticals Inc. and Piramal Healthcare Limited. North America was the largest region in the hormonal contraceptives market in 2022. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market during the forecast period. The regions covered in the global hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global hormonal contraceptives market is segmented - 1) By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Other Products 2) By End Users: Hospitals, Homecare Settings, Gynaecology Centers, Clinics, Ambulatory surgical centers 3) By Hormones: Progestin-Only, Combined Hormones 4) By Distribution Channel: Drug Stores, Gynaecology/ Fertility Clinics, E-Commerce, Other Distribution Channels

Biosimilar growth hormone refers to a peptide hormone that promotes cellular regeneration, cell division, and growth in both humans and other animals. Thus, it is crucial to the advancement of humanity. It is a form of mitogen that only affects particular types of cells. The main routes of administration of biosimilar growth hormones are intravenous, subcutaneous, intramuscular, and oral. Intravenous treatment is a medical procedure that involves injecting fluids, drugs, and nutrients into a patient's vein. The different applications include growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, and others, and are distributed through various channels such as hospital and retail pharmacies, online pharmacy/pharmacy, and specialty clinics. The biosimilar growth hormone market research report is one of a series of new reports from The Business Research Company that provides biosimilar growth hormone market statistics, including biosimilar growth hormone industry global market size, regional shares, competitors with a biosimilar growth hormone market share, detailed biosimilar growth hormone market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar growth hormone industry. This biosimilar growth hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.. The global biosimilar growth hormones market grew from $0.64 billion in 2022 to $0.7 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar growth hormones market is expected to grow from $0.98 billion in 2027 at a CAGR of 8.8%. The growing number of children suffering from growth hormone deficiency is driving the growth of the global biosimilar growth hormone market. Growth hormone deficiency is caused by damage to the pituitary gland or hypothalamus, which may be the result of an abnormal formation that occurred before the child was born (congenital) or something that occurred during or after birth (acquired). Growth hormone deficiency has been identified in about 1 in every 3,800 babies. Additionally, some children acquire it later in life as a result of a brain tumor, brain operation, radiation therapy, injury, or infection. Thus, an increase in the number of children suffering from growth deficiencies drives the growth of the market. The growing awareness about the side effects caused by the continuous usage of biosimilar growth hormones is expected to restrict the growth of the market. Possible side effects of HGH use include nerve, muscle, or joint pain, swelling due to fluid in the body's tissues (edema), carpal tunnel syndrome, numbness and tingling of the skin, and high cholesterol levels. Continuous dosage of HGH can also increase the risk of diabetes and contribute to the growth of cancerous tumors, thus restraining the growth of the market. Recombinant DNA technology (rDNA technology) is increasingly being implemented in the biosimilar growth hormone industry. The development of biosimilar growth hormone by using recombinant DNA technology (rDNA technology) is an emerging trend. For instance, in 2020, rBIO was produced utilising recombinant DNA technology. Rubio can cut the cost of insulin by 30%, rendering insulin and other medications more cost-effective in the United States. In September 2020, Ligand Pharmaceuticals Incorporated (Ligand), a US-based biopharmaceutical company, acquired Pfenex Inc. for an undisclosed amount. Ligand claims that acquiring Pfenex will provide several advantages, including access to the company’s proprietary protein expression technology, partnerships with pharma firms such as Merck, Jazz Pharmaceuticals, the Serum Institute of India, and Alvogen, and the prospect of securing additional licences over the next few years by utilising Pfenex technology. Pfenex Inc. is a US-based biosimilar manufacturer. Major players in the biosimilar growth hormone market are Biopartners and LG Chem, Amega Biotech, Eli Lilly and Company, Genetech Inc., Novartis AG, Zhongshan Hygene Biopharm Co. Ltd., Merck, Sanofi S.A., Biosidus, and Ferring Pharmaceuticals. North America was the largest region in the biosimilar growth hormone market in 2022. The Middle East is expected to be the fastest-growing region in the global biosimilar growth hormones market during the forecast period. The regions covered in the global biosimilar growth hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar growth hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar growth hormone market consists of sales of teriparatide, follitropin alfa, insulin, and somatropin. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar growth hormones market is segmented - 1) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular, Oral 2) By Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications 3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Speciality Clinics

Parathyroid hormone refers to a substance produced by the parathyroid gland that aids in the body's storage and utilisation of calcium. High blood calcium levels are a result of parathyroid hormone levels that are greater than usual and could be a disease indicator. It is also known as PTH, parathyrin, and parathormone. The main types of products in parathyroid hormone are recombinant parathyroid hormone and parathyroid hormone analogs. Recombinant parathyroid hormone, a mimic of parathyroid hormone, is used to treat osteoporosis. The different types of diseases include hypocalcaemia, and hypoparathyroidism and are used in various sectors, such as hospitals, clinics, and others. The parathyroid hormone market research report is one of a series of new reports from The Business Research Company that provides parathyroid hormone market statistics, including parathyroid hormone industry global market size, regional shares, competitors with a parathyroid hormone market share, detailed parathyroid hormone market segments, market trends and opportunities, and any further data you may need to thrive in the parathyroid hormone industry. This parathyroid hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global parathyroid hormone market grew from $2.15 billion in 2022 to $2.26 billion in 2023 at a compound annual growth rate (CAGR) of 5.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The parathyroid hormone market is expected to grow from $2.8 billion in 2027 at a CAGR of 5.6%. The rise in the prevalence of osteoporosis is expected to drive the market for parathyroid hormones. Osteoporosis is a disease characterised by low bone mass and deterioration of bone tissue, which further leads to an increased risk of fracture. According to the International Osteoporosis Foundation, osteoporosis affects approximately 1.4 million Canadians, mainly postmenopausal women and the elderly. The parathyroid hormone, which is naturally produced by the body for regulating calcium levels, is used to reduce the risk of bone fracture in people with osteoporosis and is administered as a daily subcutaneous injection. The increase in osteoporosis is therefore expected to contribute to the growth of the parathyroid hormone market. Product recalls due to quality control issues are expected to hinder the growth of the market during the forecast period. A product recall is the process of retrieving defective or potentially unsafe goods from consumers due to safety, efficacy, or quality issues. Takeda Pharmaceutical Company issued a US recall for all doses of NATPARA (parathyroid hormone) for injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). The recall is due to a potential issue associated with rubber particulates arising from the rubber septum of the NATPARA cartridge. These factors are expected to negatively impact the growth of the market during the forecast period. Companies in the parathyroid hormone market are focusing on developing biosimilars of parathyroid-based drugs. A biosimilar is a biological product that is developed to be similar to an already FDA-approved biologic, known as the reference product. Biosimilars potentially offer consumers the opportunity to reduce their health care costs without compromising on treatment standards, which is why parathyroid hormone manufacturing companies are investing in them. For instance, in August 2020, Cadila Pharmaceuticals will launch a teriparatide biosimilar (NuPTH) meant for osteoporosis. Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, announced its decision to acquire Shire Plc for $46 billion. The acquisition is expected to accelerate the delivery of medicines to patients around the world with an expanded scale and geographical footprint by Takeda Pharmaceutical Company. It also increases the levels of the parathyroid hormone, natpara. Shire Plc is a pharmaceutical company based in the United States that specialises in innovative and rare disease drugs. Major players in the parathyroid hormone market are Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Shire, Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc. and Gedeon Richter PLC. North America was the largest region in the parathyroid hormone market in 2022. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market during the forecast period. The regions covered in the global parathyroid hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the parathyroid hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The parathyroid hormone market consists of sales of parathormone and calcitonin. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global parathyroid hormone market is segmented - 1) By Disease Type: Hypocalcaemia, Hypoparathyroidism 2) By End-User: Hospitals, Clinics, Othe End-Users 3) By Product Type: Recombinant Parathtyoid Hormone, Parathyroid Hormone Analogues